α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: A role for mitochondrial bioenergetics

Blood

Volumn 124, Issue 18, 2014, Pages 2881-2891

  Marcondes, A Mario ^a,b   Karoopongse, Ekapun ^a   Lesnikova, Marina ^a   Margineantu, Daciana ^a   Welte, Tobias ^c   Dinarello, Charles A ^d,e   Hockenbery, David ^a,b   Janciauskiene, Sabina ^c   Deeg, H Joachim ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2 INTEGRIN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR FOXP3; LACTIC ACID DERIVATIVE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SUPEROXIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BIOENERGY; BIOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GLYCOLYSIS; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MITOCHONDRION; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN DONOR; OXIDATIVE PHOSPHORYLATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR CELL; ANIMAL; BLOOD; C57BL MOUSE; CELL PROLIFERATION; DEMOGRAPHY; DONOR; DRUG EFFECTS; ENERGY METABOLISM; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; OXYGEN CONSUMPTION; SIBLING; UPREGULATION;

ALPHA 1-ANTITRYPSIN; ANIMALS; ANTIGENS, CD11C; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DEMOGRAPHY; ENERGY METABOLISM; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY TESTING; HUMANS; KILLER CELLS, NATURAL; LACTATES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED C57BL; MIDDLE AGED; MITOCHONDRIA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OXYGEN CONSUMPTION; SIBLINGS; SUPEROXIDES; TISSUE DONORS; UP-REGULATION;

EID: 84908577173     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570440     Document Type: Article

References (51)

1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008; 112(12):4371-4383.
2. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357(15):1472-1475.
3. Yu Y, Wang D, Liu C., et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood. 2011; 118(18):5011-5020.
4. Haarberg KM, Li J, Heinrichs J., et al. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood. 2013; 122(14):2500-2511.
5. Shlomchik WD, Couzens MS, Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999; 285(5426):412-415.
6. Breit SN, Wakefield D, Robinson J.P., Luckhurst E., Clark P, Penny R. The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol. 1985; 35(3):363-380.
7. Marcondes AM, Li X, Tabellini L., et al. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 2011; 118(18):5031-5039.
8. Tawara I, Sun Y, Lewis E.C., et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA. 2012; 109(2):564-569.
9. Brennan TV, Lin L, Huang X., et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012; 120(14):2899-2908.
10. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2011; 51(2):244-251.
11. Lewis EC, Mizrahi M, Toledano M., et al. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA. 2008; 105(42): 16236-16241.
12. Aleporou-Marinou V, Pappa H, Marinou H., Yalouris P, Patargias T. Presence of alpha1-antitrypsin and transferrin in human follicular fluid-correlation with fertilization. Comp Biochem Physiol B Biochem Mol Biol. 2002; 133(1): 105-111.
13. Churg A, Dai J, Zay K., et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001; 81(8):1119-1131.
14. Joosten LA, Netea MG, Kim S.H., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 2006; 103(9):3298-3303.
15. Kim SH, Han SY, Azam T, Yoon D.Y., Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005; 22(1):131-142.
16. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007; 8(2):191-197.
17. Cooke KR, Kobzik L, Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996; 88(8):3230-3239.
18. Zeiser R, Youssef S, Baker J., Kambham N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007; 110(13):4588-4598.
19. Ozeri E, Mizrahi M, Shahaf G., Lewis EC. α-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012; 189(1):146-153.
20. Matte CC, Liu J, Cormier J., et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004; 10(9):987-992.
21. Diefenbach A, Jamieson AM, Liu S.D., Shastri N., Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000; 1(2):119-126.
22. Peraldi MN, Berrou J, Dulphy N., et al. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from endstage renal disease patients. J Immunol. 2009; 182(3):1696-1705.
23. Maes OC, Kravitz S, Mawal Y., et al. Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis. 2006; 24(1):89-100.
24. Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004; 59(2):164-169.
25. Donato LJ, Jenkins SM, Smith C, Katzmann J.A., Snyder MR. Reference and interpretive ranges for α(1)-antitrypsin quantitation by phenotype in adult and pediatric populations. Am J Clin Pathol. 2012; 138(3):398-405.
26. Sandström CS, Ohlsson B, Melander O., Westin U, Mahadeva R, Janciauskiene S. An association between type 2 diabetes and alpha-antitrypsin deficiency. Diabet Med. 2008; 25(11):1370-1373.
27. Funding M, Vorum H, Nexø E, Ehlers N. Alpha-1-antitrypsin in aqueous humour from patients with corneal allograft rejection. Acta Ophthalmol Scand. 2005; 83(3):379-384.
28. Akl A, Luo S, Wood KJ. Induction of transplantation tolerance-the potential of regulatory T cells. Transpl Immunol. 2005; 14(3-4): 225-230.
29. Xu D, Wang FS. Are non-traditional CD4(+) CD69(+) CD25(-) regulatory T cells involved in disease progression of human hepatocellular carcinoma? J Gastroenterol Hepatol. 2011; 26(10):1469-1470.
30. Hu J, Wan Y. Tolerogenic dendritic cells and their potential applications. Immunology. 2011; 132(3): 307-314.
31. Morelli AE, Antonysamy MA, Takayama T, et al. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus. J Immunol. 2000; 165(1):226-237.
32. Sato K, Yamashita N, Yamashita N., Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003; 18(3): 367-379.
33. Cavet J, Middleton PG, Segall M, Noreen H., Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999; 94(11):3941-3946.
34. Lin M-T, Storer B., Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003; 349(23):2201-2210.
35. Marzatico F, Gaetani P, Tartara F., et al. Antioxidant status and alpha1-antiproteinase activity in subarachnoid hemorrhage patients. Life Sci. 1998; 63(10):821-826.
36. Aldonyte R, Jansson L, Janciauskiene S. Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. BMC Cell Biol. 2004; 5:11.
37. Koulmanda M, Bhasin M, Hoffman L., et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA. 2008; 105(42):16242-16247.
38. Marcondes AMQ, Lesnikova M, Georges G., Mielcarek M, Dinarello CA, Deeg HJ. α1 anti-trypsin (AAT-1), augments DCs and frequency of regulatory T cells (T reg), modulates GVHD, and increases survival after allogeneic transplantation. Biol Blood Marrow Transplant. 2012; 18 (suppl 2): S223.
39. Ohata J, Sakurai J, Saito K., Tani K, Asano S, Azuma M. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol. 2002; 129(1):61-68.
40. Savani BN, Mielke S, Adams S., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007; 21(10):2145-2152.
41. Verheyden S, Schots R, Duquet W., Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005; 19(8): 1446-1451.
42. Miller JS, Warren EH, van den Brink MR, et al. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant. 2010; 16(5):565-586.
43. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; 114(5): 1099-1109.
44. Gatza E, Wahl DR, Opipari A.W., et al. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med. 2011; 3(67):67ra8.
45. Yamashita K, Ollinger R, McDaid J., et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J. 2006; 20(6):776-778.
46. Shen Z, Teng X, Qian X., et al. Immunoregulation effect by overexpression of heme oxygenase-1 on cardiac xenotransplantation. Transplant Proc. 2011; 43(5):1994-1997.
47. Ochayon DE, Mizrahi M, Shahaf G., Baranovski BM, Lewis EC. Human α1-antitrypsin binds to heat-shock protein gp96 and protects from endogenous gp96-mediated injury In vivo. Front Immunol. 2013; 4:320.
48. Bergin DA, Reeves EP, Hurley K, et al. The circulating proteinase inhibitor alpha-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med. 2014; 6(217): 217ra1.
49. Piantadosi CA, Carraway MS, Babiker A, Suliman HB. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res. 2008; 103(11):1232-1240.
50. Saha A, Aoyama K, Taylor P.A., et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013; 122(17):3062-3073.
51. Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta. 1998; 1366(1-2): 177-196.